309 related articles for article (PubMed ID: 14716737)
1. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
König JE; Senge T; Allhoff EP; König W
Prostate; 2004 Feb; 58(2):121-9. PubMed ID: 14716737
[TBL] [Abstract][Full Text] [Related]
2. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.
Steiner GE; Newman ME; Paikl D; Stix U; Memaran-Dagda N; Lee C; Marberger MJ
Prostate; 2003 Aug; 56(3):171-82. PubMed ID: 12772186
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells.
Subbarayan V; Sabichi AL; Llansa N; Lippman SM; Menter DG
Cancer Res; 2001 Mar; 61(6):2720-6. PubMed ID: 11289153
[TBL] [Abstract][Full Text] [Related]
4. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium.
Wang W; Bergh A; Damber JE
Prostate; 2004 Sep; 61(1):60-72. PubMed ID: 15287094
[TBL] [Abstract][Full Text] [Related]
5. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways.
Penna G; Fibbi B; Amuchastegui S; Corsiero E; Laverny G; Silvestrini E; Chavalmane A; Morelli A; Sarchielli E; Vannelli GB; Gacci M; Colli E; Maggi M; Adorini L
Prostate; 2009 Apr; 69(5):480-93. PubMed ID: 19107880
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.
Kramer G; Steiner GE; Handisurya A; Stix U; Haitel A; Knerer B; Gessl A; Lee C; Marberger M
Prostate; 2002 Jun; 52(1):43-58. PubMed ID: 11992619
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma.
Zha S; Gage WR; Sauvageot J; Saria EA; Putzi MJ; Ewing CM; Faith DA; Nelson WG; De Marzo AM; Isaacs WB
Cancer Res; 2001 Dec; 61(24):8617-23. PubMed ID: 11751373
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclooxygenase-2 in prostate carcinoma.
Yoshimura R; Sano H; Masuda C; Kawamura M; Tsubouchi Y; Chargui J; Yoshimura N; Hla T; Wada S
Cancer; 2000 Aug; 89(3):589-96. PubMed ID: 10931458
[TBL] [Abstract][Full Text] [Related]
9. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA.
Banerjee AG; Liu J; Yuan Y; Gopalakrishnan VK; Johansson SL; Dinda AK; Gupta NP; Trevino L; Vishwanatha JK
Mol Cancer; 2003 Oct; 2():34. PubMed ID: 14613585
[TBL] [Abstract][Full Text] [Related]
10. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L
J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro.
Okamoto M; Lee C; Oyasu R
Cancer Res; 1997 Jan; 57(1):141-6. PubMed ID: 8988055
[TBL] [Abstract][Full Text] [Related]
12. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.
Penna G; Mondaini N; Amuchastegui S; Degli Innocenti S; Carini M; Giubilei G; Fibbi B; Colli E; Maggi M; Adorini L
Eur Urol; 2007 Feb; 51(2):524-33; discussion 533. PubMed ID: 16905241
[TBL] [Abstract][Full Text] [Related]
13. Regulation of interleukin-8 expression in human prostate cancer cells by insulin-like growth factor-I and inflammatory cytokines.
Kooijman R; Himpe E; Potikanond S; Coppens A
Growth Horm IGF Res; 2007 Oct; 17(5):383-91. PubMed ID: 17513150
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of synoviocyte COX-2 through interactions with T lymphocytes: role of interleukin 17 and tumor necrosis factor-alpha.
Stamp LK; Cleland LG; James MJ
J Rheumatol; 2004 Jul; 31(7):1246-54. PubMed ID: 15229940
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of IL-6, TNF-alpha, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells.
Harizi H; Norbert G
Cell Immunol; 2004 Apr; 228(2):99-109. PubMed ID: 15219461
[TBL] [Abstract][Full Text] [Related]
16. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
17. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
Niiya M; Niiya K; Kiguchi T; Shibakura M; Asaumi N; Shinagawa K; Ishimaru F; Kiura K; Ikeda K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2003 Nov; 52(5):391-8. PubMed ID: 12908082
[TBL] [Abstract][Full Text] [Related]
18. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.
Lee LM; Pan CC; Cheng CJ; Chi CW; Liu TY
Anticancer Res; 2001; 21(2B):1291-4. PubMed ID: 11396201
[TBL] [Abstract][Full Text] [Related]
19. The differential effects of IL-1 and TNF-alpha on proinflammatory cytokine and matrix metalloproteinase expression in human chondrosarcoma cells.
Shi J; Schmitt-Talbot E; DiMattia DA; Dullea RG
Inflamm Res; 2004 Aug; 53(8):377-89. PubMed ID: 15316669
[TBL] [Abstract][Full Text] [Related]
20. Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation.
Tsai CY; Lee TS; Kou YR; Wu YL
J Cell Biochem; 2009 Oct; 108(2):489-98. PubMed ID: 19626664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]